Australia's most trusted
source of pharma news
Posted 15 August 2025 AM
Nine companies are a step closer to adding new labels to their drugs after the TGA accepted their Type C applications for review in June.
Moderna is looking to carve out a new niche for mRESVIA in the increasingly flooded RSV vaccine market by targeting younger Aussies. The TGA is considering extending the use of the mRNA vaccine, currently approved for certain adults from 60 years of age, for adults 18 through to 59 years of age who are at increased risk of RSV spreading to lower parts of the respiratory system, such as the lungs.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.